secwatch.observer — SEC 8-K summary
======================================

Issuer:     Viking Therapeutics, Inc. (VKTX)
CIK:        0001607678
Form:       8-K
Filed at:   2022-05-26T23:59:59+00:00
Accession:  0001564590-22-021417
Event type: other
Sentiment:  neutral
Materiality: 0.15
Item codes: 5.07
LLM model:  deepseek-v4-flash:cloud@v2

Viking Therapeutics shareholders elect directors, ratify auditor, approve say-on-pay at 2022 annual meeting
--------------------------------------------------------------------------------

- Elected Matthew W. Foehr and Charles A. Rowland, Jr. as Class I directors; Foehr received 17.1M votes for, Rowland 16.3M.
- Ratified Marcum LLP as independent auditor for FY2022 with 50.7M votes for, 0.4M against, 66K abstentions.
- Advisory vote on named executive officer compensation passed with 25.2M for, 1.7M against, 0.9M abstain.
- Broker non-votes of about 23.4M shares on director elections and say-on-pay due to uninstructed shares.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1607678/000156459022021417/0001564590-22-021417-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1607678/000156459022021417/vktx-8k_20220524.htm
  HTML page:      https://secwatch.observer/filing/0001564590-22-021417

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer